# Ruxolitinib in Operable Head and Neck Cancer

> **NCT03153982** · PHASE2 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 16 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT03153982
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-08
- **Primary completion:** 2023-10-18
- **Final completion:** 2023-10-18
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2024-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03153982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03153982, "Ruxolitinib in Operable Head and Neck Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03153982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*